子宮內膜異位症市場－全球及區域分析：按國家/地區分類－分析與預測（2025-2035）

Endometriosis Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035

出版日期: 2025年11月10日 | 出版商:

BIS Research | 英文 90 Pages | 商品交期: 1-5個工作天內

價格

簡介目錄圖表

全球子宮內膜異位症市場分析與預測（2025-2035）

子宮內膜異位症是一種慢性疾病，子宮內膜類似的組織生長在子宮外，引起疼痛、炎症，有時會導致不孕。

這些異常增生組織，稱為子宮內膜病變，可出現在卵巢、輸卵管、子宮外表面、骨盆腔其他部位。這些增生組織會隨著月經週期中的荷爾蒙變化而改變，並引起出血、發炎和疼痛，尤其是在月經期間。

子宮內膜異位症市場的發展受到患病率和公眾認知度不斷提高、治療選擇日益增多以及人們對預防不孕症日益成長的關注等因素的推動。隨著人們對子宮內膜異位症的認知不斷加深，確診病例數也不斷增加。由於其症狀與其他常見疾病（如大腸激躁症(IBS) 和骨盆腔炎 (PID)）相似，因此常常被漏診。提高大眾對子宮內膜異位症的認知和理解是推動該藥物市場成長的關鍵因素。根據美國婦產科醫師學會統計，約有 10% 的育齡女性患有子宮內膜異位症，這意味著全球約有 1.9 億女性受到該疾病的困擾。

此外，影像技術、腹腔鏡檢查和基因標記技術的進步使得子宮內膜異位症的診斷更加早期，導致患者數量增加，治療需求也隨之成長。診斷準確性的提高促使患者尋求早期醫療干預和治療，從而推動了市場成長。治療方法也發生了重大轉變，從傳統的疼痛管理（非類固醇抗發炎藥、荷爾蒙療法）轉向標靶治療。

子宮內膜異位症的平均診斷延遲時間為7-10年，主要原因是其症狀與其他疾病重疊。這種診斷延遲會影響治療的啟動時機，加速疾病進展並降低治療效果。此外，缺乏可靠的非侵入性診斷工具（腹腔鏡檢查除外）也是早期發現的一大障礙。

此外，儘管現有治療方法，特別是荷爾蒙療法（例如促性腺激素釋放促效劑）療效顯著，但它們也會引起嚴重的副作用，例如潮熱、骨骼密度下降和情緒波動。長期用藥的需求可能導致患者依從性差，並轉而使用其他療法，限制了市場潛力。這給製藥公司帶來了挑戰，他們需要開發出更有效、副作用更少的治療方法。此外，子宮內膜異位症的治療費用可能很高，尤其是手術和生物製藥等先進治療方法。另外，不孕症治療的費用也可能造成經濟負擔。在低收入和中等收入國家，獲得充足的醫療保健和藥物仍然是一個難題。

子宮內膜異位症治療市場正朝著標靶治療方向發展。未來的治療方法很可能針對與子宮內膜異位症相關的基因突變和子宮內膜組織行為，從而提供更有效、副作用更少的治療方案。

隨著研究不斷揭示子宮內膜異位症的遺傳和分子機制，個人化治療方案正日益成為一種趨勢。這種方法涉及基因檢測和精準醫療，旨在針對疾病進程中涉及的特定分子路徑進行治療。各公司正致力於精準醫療，以期根據個體的基因譜開發出有效的治療方法。

此外，非荷爾蒙療法在滿足無法耐受或不願接受荷爾蒙療法的患者的未滿足需求方面具有巨大潛力。針對子宮內膜病變疼痛途徑、發炎和血管生成的藥物有望佔據可觀的市場。

隨著越來越多的女性推遲生育，子宮內膜異位症患者對保留生育功能的治療方法的需求日益成長。這包括促性腺激素釋放激素拮抗劑、達那唑和Aromatase抑制劑等藥物，這些藥物能夠在治療子宮內膜異位症的同時，避免增加不孕風險。投資於能夠兼顧疾病控制和生育力保護的治療方法的公司有望從中受益。

子宮內膜異位症市場的競爭格局由幾家主要參與企業主導，其中包括開發創新治療方法的大型製藥企業和生物技術公司。

本報告對全球子宮內膜異位症市場進行了分析，並概述了市場狀況、區域趨勢以及參與該市場的公司的概況。

Endometriosis is a chronic medical condition where tissue similar to the lining of the uterus (the endometrium) grows outside the uterus, causing pain, inflammation, and sometimes infertility. The abnormal growths, known as endometrial lesions, can be found on the ovaries, fallopian tubes, the outer surface of the uterus, and in other areas of the pelvic cavity. These growths respond to hormonal changes in the menstrual cycle, leading to bleeding, irritation, and pain, particularly during menstruation.

The endometriosis market is driven by rising prevalence and awareness, expanding treatment options, and growing focus on fertility preservation. As awareness about endometriosis increases, the number of diagnosed cases is rising. The condition is often underdiagnosed due to its symptoms being similar to other common conditions like irritable bowel syndrome (IBS) or pelvic inflammatory disease (PID). Better awareness and understanding of endometriosis are key drivers in the growth of the drug market. According to the American College of Obstetricians and Gynecologists, approximately 10% of women of reproductive age have endometriosis, translating to an estimated 190 million women worldwide.

Moreover, with advancements in imaging techniques, laparoscopy, and genetic markers, endometriosis is being diagnosed earlier. This leads to an increase in the patient population, thus driving the demand for treatments. A better diagnosis means patients are now seeking early intervention and management through drugs, which fosters market growth. Also, there has been a significant shift in treatment approaches, from traditional pain management (NSAIDs, hormonal therapies) to targeted therapies.

The average delay in diagnosing endometriosis is 7 to 10 years, primarily because its symptoms overlap with other conditions. This delay impacts treatment initiation and affects the progression of the disease and reduces the effectiveness of treatments. Furthermore, the lack of reliable non-invasive diagnostic tools (beyond laparoscopy) creates a barrier to early detection.

In addition, existing treatments, particularly hormonal therapies such as GnRH agonists, are effective but can lead to significant side effects, such as hot flashes, bone density loss, and mood swings. The need for long-term medication can result in poor adherence or switching to alternative therapies, limiting market potential. This presents a challenge for pharmaceutical companies to develop more effective treatments with fewer side effects. Furthermore, endometriosis treatment can be expensive, particularly for advanced therapies like surgery or biologics. Additionally, the cost of infertility treatments can be a financial burden. In low- and middle-income countries, access to appropriate care and medications remains a challenge.

The market for endometriosis is increasingly leaning toward targeted therapies. Future therapies are likely to target genetic mutations associated with endometriosis and endometrial tissue behavior, offering more effective treatments with fewer side effects.

As research continues to uncover the genetic and molecular mechanisms of endometriosis, there is a growing trend toward personalized treatment plans. This approach includes genetic testing and precision medicine that target specific molecular pathways involved in the disease process. Companies are focusing on precision medicine to develop therapies that work for individuals based on their genetic profiles.

Additionally, non-hormonal treatments present a significant opportunity to address the unmet need of patients who cannot tolerate or do not wish to use hormonal therapies. Drugs targeting pain pathways, inflammation, or vascularization of endometrial lesions could capture substantial market share.

With a growing number of women delaying childbirth, there is an increasing demand for fertility-sparing treatments for women with endometriosis. This includes medications that treat endometriosis without compromising fertility, such as GnRH antagonists, Danazol, and aromatase inhibitors. Companies investing in therapies that offer a balance between disease management and fertility preservation stand to benefit.

The competitive landscape of the endometriosis market is dominated by several key players, including both large pharmaceutical companies and biotech firms that are advancing innovative therapies.

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Endometriosis Market: Industry Outlook

1.1 Market Overview
1.2 Epidemiological Analysis
1.3 Regulatory Landscape
1.4 Key Trends
1.5 Clinical Trial Analysis
1.6 Market Dynamics
- 1.6.1 Impact Analysis
- 1.6.2 Market Drivers
- 1.6.3 Market Restraint
- 1.6.4 Market Opportunities

2. Global Endometriosis Market, by Region, $Million, 2023-2035

2.1 North America
- 2.1.1 Market Dynamics
- 2.1.2 Market Size and Forecast
  - 2.1.2.1 North America Endometriosis Market, by Country
    - 2.1.2.1.1 U.S.
2.2 Europe
- 2.2.1 Market Dynamics
- 2.2.2 Market Size and Forecast
  - 2.2.2.1 Europe Endometriosis Market, by Country
    - 2.2.2.1.1 Germany
    - 2.2.2.1.2 U.K.
    - 2.2.2.1.3 France
    - 2.2.2.1.4 Italy
    - 2.2.2.1.5 Spain
2.3 Asia-Pacific
- 2.3.1 Market Dynamics
- 2.3.2 Market Size and Forecast
  - 2.3.2.1 Asia-Pacific Endometriosis Market, by Country
    - 2.3.2.1.1 Japan

3. Global Endometriosis Market -Competitive Landscape and Company Profiles

3.1 Competitive Landscape
- 3.1.1 Key Developments and Strategies
  - 3.1.1.1 Funding Activities
  - 3.1.1.2 Mergers and Acquisitions
  - 3.1.1.3 Regulatory Approvals
  - 3.1.1.4 Partnerships, Collaborations and Business Expansions
3.2 Company Profiles
- 3.2.1 Pfizer, Inc.
  - 3.2.1.1 Overview
  - 3.2.1.2 Top Products / Product Portfolio
  - 3.2.1.3 Top Competitors
  - 3.2.1.4 Target Customers/End-Users
  - 3.2.1.5 Key Personnel
  - 3.2.1.6 Analyst View
- 3.2.2 AbbVie
  - 3.2.2.1 Overview
  - 3.2.2.2 Top Products / Product Portfolio
  - 3.2.2.3 Top Competitors
  - 3.2.2.4 Target Customers/End-Users
  - 3.2.2.5 Key Personnel
  - 3.2.2.6 Analyst View
- 3.2.3 Bayer AG
  - 3.2.3.1 Overview
  - 3.2.3.2 Top Products / Product Portfolio
  - 3.2.3.3 Top Competitors
  - 3.2.3.4 Target Customers/End-Users
  - 3.2.3.5 Key Personnel
  - 3.2.3.6 Analyst View
- 3.2.4 Astellas Pharma
  - 3.2.4.1 Overview
  - 3.2.4.2 Top Products / Product Portfolio
  - 3.2.4.3 Top Competitors
  - 3.2.4.4 Target Customers/End-Users
  - 3.2.4.5 Key Personnel
  - 3.2.4.6 Analyst View
- 3.2.5 Kissei Pharmaceutical Co., Ltd.
  - 3.2.5.1 Overview
  - 3.2.5.2 Top Products / Product Portfolio
  - 3.2.5.3 Top Competitors
  - 3.2.5.4 Target Customers/End-Users
  - 3.2.5.5 Key Personnel
  - 3.2.5.6 Analyst View
- 3.2.6 NRx Pharmaceuticals, Inc. (Hope Medicine Inc.)
  - 3.2.6.1 Overview
  - 3.2.6.2 Top Products / Product Portfolio
  - 3.2.6.3 Top Competitors
  - 3.2.6.4 Target Customers/End-Users
  - 3.2.6.5 Key Personnel
  - 3.2.6.6 Analyst View
- 3.2.7 Gesynta Pharma AB
  - 3.2.7.1 Overview
  - 3.2.7.2 Top Products / Product Portfolio
  - 3.2.7.3 Top Competitors
  - 3.2.7.4 Target Customers/End-Users
  - 3.2.7.5 Key Personnel
  - 3.2.7.6 Analyst View
- 3.2.8 Ananda Pharma
  - 3.2.8.1 Overview
  - 3.2.8.2 Top Products / Product Portfolio
  - 3.2.8.3 Top Competitors
  - 3.2.8.4 Target Customers/End-Users
  - 3.2.8.5 Key Personnel
  - 3.2.8.6 Analyst View
- 3.2.9 Others